Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377018098> ?p ?o ?g. }
- W4377018098 endingPage "504" @default.
- W4377018098 startingPage "494" @default.
- W4377018098 abstract "Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia. To address the ongoing need for improved symptomatic treatments for individuals with Huntington's disease, valbenazine was evaluated for the treatment of chorea associated with Huntington's disease.KINECT-HD (NCT04102579) was a phase 3, randomised, double-blind, placebo-controlled trial, performed in 46 Huntington Study Group sites in the USA and Canada. The study included adults with genetically confirmed Huntington's disease and chorea (Unified Huntington's Disease Rating Scale [UHDRS] Total Maximal Chorea [TMC] score of 8 or higher) who were randomly assigned (1:1) via an interactive web response system (with no stratification or minimisation) to oral placebo or valbenazine (≤80 mg, as tolerated) for 12 weeks of double-blinded treatment. The primary endpoint was a least-squares mean change in UHDRS TMC score from the screening and baseline period (based on the average of screening and baseline values for each participant) to the maintenance period (based on the average of week 10 and 12 values for each participant) in the full-analysis set using a mixed-effects model for repeated measures. Safety assessments included treatment-emergent adverse events, vital signs, electrocardiograms, laboratory tests, clinical tests for parkinsonism, and psychiatric assessments. The double-blind placebo-controlled period of KINECT-HD has been completed, and an open-label extension period is ongoing.KINECT-HD was performed from Nov 13, 2019, to Oct 26, 2021. Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo). The full-analysis set included 68 women and 57 men. Least-squares mean changes from the screening and baseline period to the maintenance period in the UHDRS TMC score were -4·6 for valbenazine and -1·4 for placebo (least-squares mean difference -3·2, 95% CI -4·4 to -2·0; p<0·0001). The most commonly reported treatment-emergent adverse event was somnolence (ten [16%] with valbenazine, two [3%] with placebo). Serious treatment-emergent adverse events were reported in two participants in the placebo group (colon cancer and psychosis) and one participant in the valbenazine group (angioedema because of allergic reaction to shellfish). No clinically important ch anges in vital signs, electrocardiograms, or laboratory tests were found. No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.In individuals with Huntington's disease, valbenazine resulted in improvement in chorea compared with placebo and was well tolerated. Continued research is needed to confirm the long-term safety and effectiveness of this medication throughout the disease course in individuals with Huntington's disease-related chorea.Neurocrine Biosciences." @default.
- W4377018098 created "2023-05-19" @default.
- W4377018098 creator A5000577229 @default.
- W4377018098 creator A5002882213 @default.
- W4377018098 creator A5003956881 @default.
- W4377018098 creator A5004438410 @default.
- W4377018098 creator A5005959130 @default.
- W4377018098 creator A5006291254 @default.
- W4377018098 creator A5007105077 @default.
- W4377018098 creator A5010258740 @default.
- W4377018098 creator A5012147087 @default.
- W4377018098 creator A5012309972 @default.
- W4377018098 creator A5013990984 @default.
- W4377018098 creator A5016152516 @default.
- W4377018098 creator A5017329873 @default.
- W4377018098 creator A5017950684 @default.
- W4377018098 creator A5018717061 @default.
- W4377018098 creator A5019755853 @default.
- W4377018098 creator A5020418567 @default.
- W4377018098 creator A5020960375 @default.
- W4377018098 creator A5021345434 @default.
- W4377018098 creator A5021360402 @default.
- W4377018098 creator A5021954299 @default.
- W4377018098 creator A5022620886 @default.
- W4377018098 creator A5022643196 @default.
- W4377018098 creator A5022846191 @default.
- W4377018098 creator A5023047953 @default.
- W4377018098 creator A5025359570 @default.
- W4377018098 creator A5025490072 @default.
- W4377018098 creator A5026268308 @default.
- W4377018098 creator A5027035037 @default.
- W4377018098 creator A5027745248 @default.
- W4377018098 creator A5028242243 @default.
- W4377018098 creator A5029320452 @default.
- W4377018098 creator A5029810262 @default.
- W4377018098 creator A5030697542 @default.
- W4377018098 creator A5031666779 @default.
- W4377018098 creator A5032726191 @default.
- W4377018098 creator A5034678406 @default.
- W4377018098 creator A5036151807 @default.
- W4377018098 creator A5037062994 @default.
- W4377018098 creator A5039815889 @default.
- W4377018098 creator A5042094115 @default.
- W4377018098 creator A5044121181 @default.
- W4377018098 creator A5044750611 @default.
- W4377018098 creator A5045713119 @default.
- W4377018098 creator A5046060828 @default.
- W4377018098 creator A5046178026 @default.
- W4377018098 creator A5046181654 @default.
- W4377018098 creator A5047355787 @default.
- W4377018098 creator A5050625144 @default.
- W4377018098 creator A5051157379 @default.
- W4377018098 creator A5051418285 @default.
- W4377018098 creator A5052215358 @default.
- W4377018098 creator A5052807731 @default.
- W4377018098 creator A5054261106 @default.
- W4377018098 creator A5054911069 @default.
- W4377018098 creator A5056165382 @default.
- W4377018098 creator A5058689028 @default.
- W4377018098 creator A5058898220 @default.
- W4377018098 creator A5059323962 @default.
- W4377018098 creator A5061861586 @default.
- W4377018098 creator A5063054008 @default.
- W4377018098 creator A5063101878 @default.
- W4377018098 creator A5064135529 @default.
- W4377018098 creator A5067113888 @default.
- W4377018098 creator A5067251493 @default.
- W4377018098 creator A5067840969 @default.
- W4377018098 creator A5069239813 @default.
- W4377018098 creator A5070122226 @default.
- W4377018098 creator A5070581787 @default.
- W4377018098 creator A5071159281 @default.
- W4377018098 creator A5071854156 @default.
- W4377018098 creator A5073318519 @default.
- W4377018098 creator A5074187010 @default.
- W4377018098 creator A5074354213 @default.
- W4377018098 creator A5075209557 @default.
- W4377018098 creator A5076442216 @default.
- W4377018098 creator A5076862436 @default.
- W4377018098 creator A5077157589 @default.
- W4377018098 creator A5079614920 @default.
- W4377018098 creator A5080921373 @default.
- W4377018098 creator A5080973366 @default.
- W4377018098 creator A5081166638 @default.
- W4377018098 creator A5082179442 @default.
- W4377018098 creator A5082724740 @default.
- W4377018098 creator A5084937714 @default.
- W4377018098 creator A5085703266 @default.
- W4377018098 creator A5086726410 @default.
- W4377018098 creator A5087774322 @default.
- W4377018098 creator A5088153919 @default.
- W4377018098 creator A5089396631 @default.
- W4377018098 creator A5090800338 @default.
- W4377018098 creator A5091641948 @default.
- W4377018098 creator A5091971989 @default.
- W4377018098 creator A5091971990 @default.
- W4377018098 creator A5091971991 @default.
- W4377018098 creator A5091971992 @default.